'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Alkem Laboratories has declined 0.74% to Rs 3414.67 crore. Operating profit margin has jumped from 21.71% to 22.05%, leading to 0.82% rise in operating profit to Rs 752.83 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 24.47% to 26.03%. Purchase of finished goods cost fell from 12.82% to 10.21%. Employee cost increased from 16.48% to 17.61%. Other expenses rose from 24.07% to 24.43%.
Other income rose 112.82% to Rs 134.48 crore. PBIDT rose 9.56% to Rs 887.31 crore. Provision for interest fell 7.19% to Rs 28.14 crore. Loan funds rose to Rs 1,477.90 crore as of 30 September 2024 from Rs 1,441.33 crore as of 30 September 2023. Inventories rose to Rs 2,912.18 c...
Pleaselogin & subscribe to view the full report.
More Reports
-
(01-Mar-2025)
Foseco India
OP up 17%
-
(28-Feb-2025)
Schaeffler India
Maintains double digit revenue growth and stable OPM
-
(28-Feb-2025)
Sanofi India
OP up 18.78%
-
(28-Feb-2025)
KSB
Net up 33% largely on higher sales, higher OI and lower taxation
|
|